Executive function in adults with attention-deficit/hyperactivity disorder during treatment with atomoxetine in a randomized, placebo-controlled, withdrawal study

Journal of Clinical Psychopharmacology

Volumn 34, Issue 4, 2014, Pages 461-466

  Adler, Lenard ^a,b   Tanaka, Yoko ^c   Williams, David ^d   Trzepacz, Paula T ^c,e,f,g   Goto, Taro ^c   Allen, Albert J ^c   Escobar, Rodrigo ^h   Upadhyaya, Himanshu P ^c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d SYNEOS HEALTH   (United States)

^e UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^f TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Lilly Research Laboratories   (Japan)

Author keywords

BRIEF A; CAARS Inv:SV; informant; self report

Indexed keywords

ATOMOXETINE; PLACEBO; ADRENERGIC RECEPTOR AFFECTING AGENT; PROPYLAMINE;

ADULT; ADULT DISEASE; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR RATING INVENTORY OF EXECUTIVE FUNCTION ADULT VERSION INFORMANT T SCORE; BEHAVIOR RATING INVENTORY OF EXECUTIVE FUNCTION ADULT VERSION SELF REPORT; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; EXECUTIVE FUNCTION; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PATIENT SATISFACTION; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TREATMENT DURATION; WORKING MEMORY; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DRUG EFFECTS; PSYCHOLOGY; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME; YOUNG ADULT;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DOUBLE-BLIND METHOD; EXECUTIVE FUNCTION; FEMALE; HUMANS; MALE; PROPYLAMINES; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903700772     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000138     Document Type: Article

References (35)

1. Bloom B, Cohen RA, Freeman G. Summary health statistics for U.S. children: National Health Interview Survey, 2010. Vital Health Stat 10. 2011;10:1-80.
2. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163:716-723. (Pubitemid 44464584)
3. Brown TE. ADD/ADHD and impaired executive function in clinical practice. Curr Psychiatry Rep. 2008;10:407-411.
4. Willcutt EG, Doyle AE, Nigg JT, et al. Validity of the executive function theory of attention-deficit/hyperactivity disorder: a meta-analytic review. Biol Psychiatry. 2005;57:1336-1346. (Pubitemid 40798553)
5. Doyle AE. Executive functions in attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2006;67(Suppl 8):21-26. (Pubitemid 44385603)
6. Barkley RA. Differential diagnosis of adults with ADHD: the role of executive function and self-regulation. J Clin Psychiatry. 2010;71:e17.
7. Barkley RA, Murphy KR. Impairment in occupational functioning and adult ADHD: the predictive utility of executive function (EF) ratings versus EF tests. Arch Clin Neuropsychol. 2010;25:157-173.
8. Stavro GM, Ettenhofer ML, Nigg JT. Executive functions and adaptive functioning in young adult attention-deficit/hyperactivity disorder. J Int Neuropsychol Soc. 2007;13:324-334. (Pubitemid 46487362)
9. Mao AR, Brams M, Babcock T, et al. A physician's guide to helping patients with ADHD find success in the workplace. Postgrad Med. 2011;123:60-70.
10. Young S, Thome J. ADHD and offenders. World J Biol Psychiatry. 2011;12(Suppl 1):124-128.
11. Canu WH, Carlson CL. Rejection sensitivity and social outcomes of young adult men with ADHD. J Atten Disord. 2007;10:261-275.
12. Paulson JF, Buermeyer C, Nelson-Gray RO. Social rejection and ADHD in young adults: an analogue experiment. J Atten Disord. 2005;8:127-135. (Pubitemid 40805796)
13. Pottinger AM, La Hee F, Asmus K. Students admitted to university who fail: hidden disabilities affecting students' performance. West Indian Med J. 2009;58:99-105.
14. Royall DR, Lauterbach EC, Cummings JL, et al. Executive control function: a review of its promise and challenges for clinical research. A report from the Committee on Research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci. 2002;14:377-405. (Pubitemid 35265986)
15. Brown TE, Landgraf JM. Improvements in executive function correlate with enhanced performance and functioning and health-related quality of life: evidence from 2 large, double-blind, randomized, placebo-controlled trials in ADHD. Postgrad Med. 2010;122:42-51.
16. Brown TE, Holdnack J, Saylor K, et al. Effect of atomoxetine on executive function impairments in adults with ADHD. J Atten Disord. 2011;15:130-138.
17. Adler L, Rubin R, Arsenault J, et al. Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) effects with atomoxetine. Poster presentation #NR9-10, at the Annual Meeting of the American Psychiatric Association; Honolulu, HI: May 14-18, 2011.
18. Dupaul GJ, Weyandt LL, Rossi JS, et al. Double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in college students with ADHD. J Atten Disord. 2012;16:202-220.
19. Michelson D, Buitelaar JK, Danckaerts M, et al. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry. 2004;43:896-904. (Pubitemid 38808495)
20. Connor DF, Findling RL, Kollins SH, et al. Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. CNS Drugs. 2010;24:755-768.
21. Brams M, Weisler R, Findling RL, et al. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder: randomized withdrawal design. J Clin Psychiatry. 2012;73:977-983.
22. Mattingly GW, Weisler RH, Young J, et al. Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. BMC Psychiatry. 2013;13:39.
23. Goodman DW. Sustained treatment effect in attention-deficit/ hyperactivity disorder: focus on long-term placebo-controlled randomized maintenance withdrawal and open-label studies. Ther Clin Risk Manag. 2013;9:121-130.
24. Camporeale A, Upadhyaya H, Ramos-Quiroga JA, et al. Safety and tolerability of atomoxetine hydrochloride in a long-term, placebo-controlled randomized withdrawal study in European and non-European adults with attention-deficit/hyperactivity disorder. Eur J Psychiatry. 2013;27:206-224.
25. Upadhyaya H, Ramos-Quiroga JA, Adler L, et al. Maintenance of response after open-label treatment with atomoxetine hydrochloride in international European and non-European adult outpatients with attention-deficit/hyperactivity disorder: a placebo-controlled, randomised withdrawal study. Eur J Psychiatry. 2013;27:185-205.
26. Roth RM, Isquith PK, Gioia GA. Behavior Rating Inventory of Executive FunctionYAdult Version. Lutz, FL: Psychological Assessment Resources, Inc; 2005.
27. Conners CK, Erhardt D, Sparrow E. Conners' Adult ADHD Rating Scales (CAARS). North Tonawanda, NY: Multi-Health Systems Inc; 1999.
28. Kessler RC, Green JG, Adler LA, et al. Structure and diagnosis of adult attention-deficit/hyperactivity disorder: analysis of expanded symptom criteria from the Adult ADHD Clinical Diagnostic Scale. Arch Gen Psychiatry. 2010;67:1168-1178.
29. Biederman J, Mick E, Fried R, et al. Are stimulants effective in the treatment of executive function deficits? Results from a randomized double blind study of OROS-methylphenidate in adults with ADHD. Eur Neuropsychopharmacol. 2011;21:508-515.
30. Yildiz O, Sismanlar SG, Memik NC, et al. Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions. Child Psychiatry Hum Dev. 2011;42:257-269.
31. Gamo NJ, Wang M, Arnsten AF. Methylphenidate and atomoxetine enhance prefrontal function through alpha2-adrenergic and dopamine D1 receptors. J Am Acad Child Adolesc Psychiatry. 2010;49:1011-1023.
32. Wilens TE, Martelon M, Fried R, et al. Do executive function deficits predict later substance use disorders among adolescents and young adults? J Am Acad Child Adolesc Psychiatry. 2011;50:141-149.
33. Biederman J, Petty CR, Wozniak J, et al. Impact of executive function deficits in youth with bipolar I disorder: a controlled study. Psychiatry Res. 2011;186:58-64.
34. Biederman J, Petty CR, Doyle AE, et al. Stability of executive function deficits in girls with ADHD: a prospective longitudinal followup study into adolescence. Dev Neuropsychol. 2008;33:44-61. (Pubitemid 351161892)
35. Wernicke JF, Adler L, Spencer T, et al. Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment. J Clin Psychopharmacol. 2004;24:30-35. (Pubitemid 38134163)